CBG and CBD target multiple inflammatory pathways with potency rivaling pharmaceutical anti-inflammatories.
Chronic inflammation underlies dozens of conditions including rheumatoid arthritis, inflammatory bowel disease, psoriasis, lupus, and metabolic syndrome. The endocannabinoid system is a master regulator of immune function, and multiple cannabinoids — particularly CBD, CBG, and CBC — have demonstrated potent anti-inflammatory activity through distinct mechanisms.
125 million adults
Americans Affected
60% of Americans have at least one chronic inflammatory condition
Prevalence
3
Key Studies
4
Cannabinoids Reviewed
Cannabinoids modulate inflammation through CB2 receptor activation on immune cells, PPARγ activation, and direct inhibition of NF-kB and COX-2 pathways. CBG demonstrated anti-inflammatory activity comparable to mesalazine in IBD models. THCA inhibits COX-2 with 10–30x greater potency than CBD at equivalent doses (2025 in vitro data).
CB2 receptors are expressed on macrophages, T cells, B cells, and dendritic cells. Activation reduces pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) and promotes anti-inflammatory cytokine production (IL-10). CBD, CBG, and CBC all activate CB2.
NF-kB is the master transcription factor for inflammatory gene expression. CBD, CBG, and THCA all inhibit NF-kB activation, reducing the transcription of COX-2, iNOS, and pro-inflammatory cytokines. THCA inhibits NF-kB with 10x greater potency than CBD.
PPARγ is a nuclear receptor that suppresses inflammatory gene expression and promotes resolution of inflammation. CBD, CBG, THCA, and THCV all activate PPARγ. PPARγ activation also has metabolic benefits relevant to inflammatory metabolic conditions.
COX-2 is the enzyme targeted by NSAIDs (ibuprofen, naproxen). THCA inhibits COX-2 with an IC50 of 0.8 µM — comparable to pharmaceutical NSAIDs. CBD and CBG also inhibit COX-2, though with lower potency than THCA.
Anti-inflammatory activity comparable to mesalazine in IBD models. Potent MRSA antibacterial activity. PPARγ activation. Strong candidate for IBD and inflammatory conditions.
CB2 agonism, NF-kB inhibition, PPARγ activation. Well-characterized anti-inflammatory profile across multiple conditions.
10–30x more potent than CBD for COX-2 inhibition in vitro (2025). Non-psychoactive. Raw cannabis juice preserves THCA. Human trials needed.
CBC activates TRPA1 and has anti-inflammatory activity in preclinical models. Contributes to full-spectrum entourage effects.
CBG for Inflammatory Bowel Disease
CBG reduced colon damage, nitric oxide production, and pro-inflammatory cytokines in murine colitis model, comparable to mesalazine.
THCA Anti-Inflammatory Activity vs. THC and CBD
THCA inhibited COX-2 (IC50 0.8 µM) and NF-kB with 10–30x greater potency than CBD. PPARγ activation confirmed.
Full-Spectrum vs. CBD Isolate: Anti-Inflammatory Dose-Response
Full-spectrum extract showed linear dose-response for anti-inflammatory activity; CBD isolate showed bell-shaped curve with narrow effective dose range.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
25mg CBD equivalent/day
Target Dose
100–300mg CBD equivalent/day
Timing
With food, twice daily
Full-spectrum preferred over isolate for anti-inflammatory use. Higher doses needed for systemic inflammation vs. anxiety.
Start Dose
Apply 2–3x daily to affected area
Target Dose
Increase frequency as needed
Timing
As needed
Topical application delivers cannabinoids to local CB2 receptors without systemic effects. Effective for joint and skin inflammation.